GlobeNewswire by notified

ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051

Share

-- Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats

MELBOURNE, Australia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Clinical-stage pharmaceutical company ENA Respiratory has been awarded a $4.38 million USD agreement from the U.S. Department of Defense (DoD) to support ongoing research and development of INNA-051, a clinical stage first-in-class broad-spectrum antiviral innate immunomodulator, administered intranasally for the prophylaxis of respiratory viral infections and their complications.

The agreement was awarded by the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, in collaboration with the Defense Innovation Unit (DIU). Funding will support studies to develop an intranasal dry powder formulation of INNA-051 and scale-up manufacturing processes.

“Populations at high risk of exposure or complications continue to be significantly affected by influenza, SARS-CoV-2, RSV and other respiratory viruses, driving increased hospitalizations and health care utilization,” said Christophe Demaison, Ph.D., co-founder and CEO of ENA Respiratory. “This agreement with the DoD recognizes the necessity of developing a broad-spectrum and fast-acting treatment to combat these debilitating viruses, and studying its use across a range of critical populations.”

The effort is expected to run for 12 months, paving the way to an Investigational New Drug (IND)-submission to the U.S. FDA aiming to support the Phase I bioequivalence study of an intranasal dry powder presentation of INNA-051. A dry powder formulation offers a number of advantages over the current spray solution formulation that will support deployment to distant or resource-limited settings and survival through the rigours of DoD logistics. INNA-051 was recently studied in a Phase 2a influenza challenge pre-exposure prophylaxis study, and results are expected soon. It was found to be well-tolerated in a Phase 1 study.

Effort funded by the U.S. Department of Defense’s Chemical and Biological Defense Program (CBDP), under Other Transaction Authority number HQ0845-23-9-0003 between ENA Respiratory Pty Ltd and the DoD. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon.

The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government or the U.S. Department of Defense.

ENDS

Notes to Editors

If you would like to arrange an interview, please contact:

About ENA Respiratory and INNA-051

ENA Respiratory is aiming to transform the prevention of respiratory viral infections in populations at-risk of complications. The company is based in Melbourne and Sydney, Australia and it has secured a Series A investment from Brandon Capital Partners’ managed funds, the Minderoo Foundation, and Uniseed.

INNA-051 is a potent innate immune TLR2/6 agonist. It is currently in clinical development for self-administered intranasal delivery to target the primary entry site of viral respiratory infections as most respiratory viruses, including SARS-CoV-2 and influenza, initially infect and replicate in nasal mucosa epithelial cells. Fast-acting and inducing a durable biologic response supporting weekly administration, INNA-051 works by recruiting innate immune cells and priming epithelial cells of the nasal mucosa to respond more quickly to infections, rapidly eliminating viruses and other pathogens before they spread throughout the body. INNA-051 and close analogues have been shown in preclinical studies to be effective against multiple respiratory viruses, including SARS-CoV-2, influenza (H1N1 and seasonal H3N2), and rhinovirus.

Key features of INNA-051 intranasal administration include minimal or no systemic bioavailability, minimal or no systemic pro-inflammatory cytokine release, no direct type I interferon upregulation which is known to be associated with fever in humans, durable immune response supporting weekly administration, and compatibility with vaccine and intranasal corticosteroids.

For more information, please visit https://enarespiratory.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alation’s Data Intelligence Project Goes Global with New Cohort of Universities30.1.2023 15:00:00 CET | Press release

Program supports the next generation of data leaders; provides hundreds of students with Alation and real-world experience REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alation Inc., the leader in enterprise data intelligence solutions, announced three new universities participating in its philanthropic initiative, The Data Intelligence Project. New universities include The University of Arkansas at Little Rock in Arkansas, The University of Cincinnati in Ohio, and The University of Stirling in Scotland. More than 420 students have used Alation in their courses to date, with this year’s global cohort providing real-world experience to hundreds of new students via Alation. The Data Intelligence Project, launched in 2021, builds a more data-literate, curious, and rational world by nurturing the next generation of data professionals. As part of The Data Intelligence Project, Alation brings its data intelligence platform, free of charge, into academic institutions and provides un

Fortinet Expands its Services and Training Offerings to Further Support SOC Teams in Preventing and Defending Against Cyber Threats30.1.2023 15:00:00 CET | Press release

Multi-Faceted Approach Accelerates Fortinet’s Global Commitment to Eliminate the Cybersecurity Skills Gap SUNNYVALE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- John Maddison, EVP of Products and CMO at Fortinet “Fortinet builds ML-driven automation into all of its SOC offerings to support short-staffed teams affected by the cybersecurity skills shortage. But technology alone won’t solve this issue, which is why we are dedicated to also delivering human-based SOC augmentation services to provide immediate support, while investing in an industry-leading training institute to close the cybersecurity skills gap. This combination of technology, services, and training enables SOC professionals to better protect their organizations from detection to incident recovery.” News Summary Fortinet® (NASDAQ: FTNT), a global leader in broad, integrated, and automated cybersecurity solutions, today announced new security operations center (SOC) augmentation services designed to help strengthen an organi

Cozycozy is the Only Accommodation Search Engine That Now Includes Airbnb, Giving Travelers the Largest Selection of Vacation Rentals Possible30.1.2023 14:30:00 CET | Press release

One search, so many possibilities - cozycozy helps users find their perfect holiday accommodation from over 100+ booking platforms, including Airbnb. NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cozycozy knows that finding the perfect place to stay can be hard. With the rise of so many vacation rental and hotel platforms comes more and more options, overwhelming travelers. "The days of having multiple tabs open to find the best deal are over," says Romain Claudel, co-founder of cozycozy. "We created cozycozy.com so travelers can see all their options in one place, without all the hassle." There are more and more vacation rentals and hotel rooms listed on several platforms, often with rates that vary. By using cozycozy, users conveniently get the lowest price possible. Their website allows users to see a comprehensive list of available options all at once, so that they get the best rates. They are the only platform in the world to include Airbnb in its search engines, letting users compa

Bank of Åland Plc: Managers' Transactions (Johansson)30.1.2023 14:30:00 CET | Press release

Bank of Åland Plc Managers' Transactions January 30, 2023, 15.30 EET Managers' Transactions --- Person subject to the notification requirement Name: Magnus Johannsson Position: Other senior manager Issuer: Ålandsbanken Abp LEI: 7437006WYM821IJ3MN73 Notification type: INITIAL NOTIFICATION Reference number: 24871/4/4 --- Transaction date: 2023-01-25 Outside a trading venue Instrument type: SHARE ISIN: FI0009001127 Nature of transaction: SUBSCRIPTION Transaction details (1): Volume: 233 Unit price: 32.98 EUR Aggregated transactions (1): Volume: 233 Volume weighted average price: 32.98 EUR For further information, please contact: Peter Wiklöf, Managing Director and Chief Executive, tel +358 40 512 7505

Ålandsbanken Abp: Transaktioner utförda av personer i ledande ställning (Johansson)30.1.2023 14:30:00 CET | Pressemelding

Ålandsbanken Abp Transaktioner utförda av personer i ledande ställning 30.1.2023 kl. 15.30 EET Transaktioner utförda av personer i ledande ställning --- Den anmälningsskyldiga Namn: Magnus Johannsson Befattning: Annan person i högsta ledningen Emittent: Ålandsbanken Abp LEI: 7437006WYM821IJ3MN73 Anmälans karaktär: FÖRSTA ANMÄLAN Referensnummer: 24871/4/4 --- Transaktionens datum: 2023-01-25 Utanför en handelsplats Instrument typ: AKTIE ISIN: FI0009001127 Transaktionens karaktär: TECKNING Detaljer om transaktionerna (1): Volym: 233 Enhetspris: 32.98 EUR Aggregerad information om transaktionerna (1): Volym: 233 Medelpris: 32.98 EUR Ytterligare information: Peter Wiklöf, Vd och koncernchef, Ålandsbanken Abp, tfn +358 40 512 7505